Nature Communications (Jul 2022)
Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
- Robert Saddawi-Konefka,
- Aoife O’Farrell,
- Farhoud Faraji,
- Lauren Clubb,
- Michael M. Allevato,
- Shawn M. Jensen,
- Bryan S. Yung,
- Zhiyong Wang,
- Victoria H. Wu,
- Nana-Ama Anang,
- Riyam Al Msari,
- Shiruyeh Schokrpur,
- Ida Franiak Pietryga,
- Alfredo A. Molinolo,
- Jill P. Mesirov,
- Aaron B. Simon,
- Bernard A. Fox,
- Jack D. Bui,
- Andrew Sharabi,
- Ezra E. W. Cohen,
- Joseph A. Califano,
- J. Silvio Gutkind
Affiliations
- Robert Saddawi-Konefka
- Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine
- Aoife O’Farrell
- Moores Cancer Center, UC San Diego
- Farhoud Faraji
- Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine
- Lauren Clubb
- Moores Cancer Center, UC San Diego
- Michael M. Allevato
- Moores Cancer Center, UC San Diego
- Shawn M. Jensen
- Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center
- Bryan S. Yung
- Moores Cancer Center, UC San Diego
- Zhiyong Wang
- Moores Cancer Center, UC San Diego
- Victoria H. Wu
- Moores Cancer Center, UC San Diego
- Nana-Ama Anang
- Moores Cancer Center, UC San Diego
- Riyam Al Msari
- Moores Cancer Center, UC San Diego
- Shiruyeh Schokrpur
- Moores Cancer Center, UC San Diego
- Ida Franiak Pietryga
- Moores Cancer Center, UC San Diego
- Alfredo A. Molinolo
- Moores Cancer Center, UC San Diego
- Jill P. Mesirov
- Moores Cancer Center, UC San Diego
- Aaron B. Simon
- Moores Cancer Center, UC San Diego
- Bernard A. Fox
- Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center
- Jack D. Bui
- Moores Cancer Center, UC San Diego
- Andrew Sharabi
- Moores Cancer Center, UC San Diego
- Ezra E. W. Cohen
- Moores Cancer Center, UC San Diego
- Joseph A. Califano
- Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine
- J. Silvio Gutkind
- Moores Cancer Center, UC San Diego
- DOI
- https://doi.org/10.1038/s41467-022-31941-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 19
Abstract
Response rates to immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC) remain low. Here the authors show that ablative treatment of tumor-draining regional lymphatics, a standard of care approach in patients, impairs the tumor response to ICI in preclinical HNSCC models.
